As Belviq Goes Off India Market, Patent Case May Fizzle
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.
You may also be interested in...
An Indian court has granted an interim injunction against Dr Reddy’s in a case concerning the alleged infringement of Eisai’s patent on Belviq. Dr Reddy’s, however, claims that Eisai is a “patent squatter” and expects to appeal against the order.
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
Coronavirus Notebook: Fauci Calls For Restraint In Disclosing Early Data; Bipartisan Lawmakers Want Warp Speed Audit
Dispatches from a world turned upside down also include the conditional approval of remdesivir in South Korea.